
SRC Biosciences (Stereology Resource Center, Inc.) is a science and technology company with over 25 years of experience, specializing in the development, commercialization, and support of stereology systems. They offer a range of products including the Stereologer® system (hardware and software), FluoroStereologer, and PainPredict. The company also provides stereology contract research organization (CRO) services and tissue processing. Their customer base spans academic centers, government agencies, and pharmaceutical companies worldwide. SRC Biosciences emphasizes innovation, user-friendliness, and affordability in their stereology solutions, including AI-based advancements for data collection. They are based in Tampa, Florida.

SRC Biosciences (Stereology Resource Center, Inc.) is a science and technology company with over 25 years of experience, specializing in the development, commercialization, and support of stereology systems. They offer a range of products including the Stereologer® system (hardware and software), FluoroStereologer, and PainPredict. The company also provides stereology contract research organization (CRO) services and tissue processing. Their customer base spans academic centers, government agencies, and pharmaceutical companies worldwide. SRC Biosciences emphasizes innovation, user-friendliness, and affordability in their stereology solutions, including AI-based advancements for data collection. They are based in Tampa, Florida.
Founded: Operating since 1995 (25+ years)
Headquarters: Tampa / Brandon, Florida
Core product: Stereologer stereology hardware & software systems
Services: Stereology CRO services, training, tissue processing
Notable support: NSF STTR/TECP awards and academic collaborations
Quantitative microscopy and unbiased stereological analysis for neuroscience and biomedical research.
1995
Life sciences / Research tools & services
1210000.00
Recorded total funding amount and last funding date reflected in company metadata.
“Federal grant support (NSF STTR/TECP) and academic/consortium collaborations; no venture or corporate investors listed”